Authors: Martha Powell, Future Science Group
The Global Antibiotic Research & Development Partnership (GARDP) is a joint initiative by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi), established in May 2016. This not-for-profit research and development organization has been set up to address global public health needs by developing and delivering new antibiotic treatments, while ensuring their appropriate use and access for all.
GARDP provides an important and alternative model to the current market-driven approaches for antibiotic research and development, which are not adequate. In our latest interview, we spoke to Jean-Pierre Paccaud, Director of Business Development & Corporate Strategy at GARDP, about the drug developer’s model and his thoughts on the wider field.
First, could you introduce yourself and give a brief summary your career to date?
I’m a molecular and cell biologist by training; I did my PhD at the University of Geneva School of Medicine (Switzerland), before doing a postdoc at the University of California, Berkeley in the US. I moved back and tenured at the University of Geneva before leaving to start-up a small enterprise working on a new approach to discover antibiotics, which after a few years merged with another company in Singapore.